Aethlon Medical (NASDAQ:AEMD – Get Free Report) and Biostage (OTCMKTS:BSTG – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.
Volatility & Risk
Aethlon Medical has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Biostage has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Aethlon Medical and Biostage, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aethlon Medical | 0 | 0 | 1 | 0 | 3.00 |
| Biostage | 0 | 0 | 0 | 0 | 0.00 |
Valuation and Earnings
This table compares Aethlon Medical and Biostage”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aethlon Medical | $570,000.00 | 16.26 | -$12.21 million | ($2.82) | -0.24 |
| Biostage | N/A | N/A | -$6.07 million | ($0.58) | -7.67 |
Biostage has lower revenue, but higher earnings than Aethlon Medical. Biostage is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
2.0% of Aethlon Medical shares are owned by institutional investors. 1.1% of Aethlon Medical shares are owned by insiders. Comparatively, 15.3% of Biostage shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Aethlon Medical and Biostage’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aethlon Medical | N/A | -160.36% | -115.74% |
| Biostage | N/A | N/A | -174.43% |
Summary
Aethlon Medical beats Biostage on 8 of the 12 factors compared between the two stocks.
About Aethlon Medical
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
About Biostage
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
